Carfilzomib + Ibrutinib clinical trials

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

This study looks at combining two drugs, Carfilzomib and Ibrutinib, to treat Waldenström's Macroglobulinemia (WM). We want to see if this combination works better than Ibrutinib alone, especially for patients whose disease has certain genetic features. It's a Phase 2 trial.